Print version | PDF version | Send article | RSS feed

Schweizerhall expands its pharmaceutical market presence with the acquisition of Novosis AG

14 Mar 2006 - Schweizerhal announced the signing of a purchase agreement for the acquisition of Novosis AG, Germany. The two companies are engaged in complementary business activities focused on dynamic segments of the pharmaceuticals industry. With Novosis, Schweizerhall gains access to another attractive market segment within specialty pharma and value added generics. This contrasts from the classic generics business by offering better margins and higher barriers to entry.
 
Luzi A. von Bidder, President of the Board of Directors of Schweizerhall Holding AG states: "The acquisition of Novosis represents an excellent strategic fit and complementary strengthening of our pharmaceutical activities. Hence it broadens our technology base for pharmaceuticals particularly in the area of advanced drug delivery, strengthens our offering for the generics industry and improves our access to research-driven pharmaceutical companies. After this purchase Schweizerhall still has sufficient financial flexibility to fuel the further expansion of the Business Unit Pharma".